168 related articles for article (PubMed ID: 32730143)
21. Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.
Giacomini PS; Rozenberg A; Metz I; Araujo D; Arbour N; Bar-Or A;
N Engl J Med; 2014 Jan; 370(5):486-8. PubMed ID: 24476450
[No Abstract] [Full Text] [Related]
22. Progressive multifocal leukoencephalopathy: what's new?
Focosi D; Marco T; Kast RE; Maggi F; Ceccherini-Nelli L; Petrini M
Neuroscientist; 2010 Jun; 16(3):308-23. PubMed ID: 20479473
[TBL] [Abstract][Full Text] [Related]
23. Progressive Multifocal Leukoencephalopathy Following Treatment With Obinutuzumab in a Patient With Non-Hodgkin Follicular Lymphoma: A Case Report.
Diavati S; Asimakopoulos JV; Galopoulos D; Konstantinou I; Argyrakos T; Toulas P; Vassilakopoulos TP; Konstantopoulos K; Angelopoulou MK
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e601-e605. PubMed ID: 33814337
[No Abstract] [Full Text] [Related]
24. Treatment of progressive multifocal Leukoencephalopathy associated with idiopathic lymphocytopenia with Nivolumab.
Fischbach L; Bauer T; Rüber T; Grobe-Einsler M; Sitter A; Radbruch A; Kaut O
J Neurol Sci; 2021 Aug; 427():117503. PubMed ID: 34051624
[No Abstract] [Full Text] [Related]
25. Progressive multifocal leukoencephalopathy: clinical and laboratory observations on a viral induced demyelinating disease in the immunodeficient patient.
Major EO; Ault GS
Curr Opin Neurol; 1995 Jun; 8(3):184-90. PubMed ID: 7551117
[TBL] [Abstract][Full Text] [Related]
26. A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.
Mazda ME; Brosch JR; Wiens AL; Bonnin JM; Kamer AP; Mattson DH; Snook RJ
Int J Neurosci; 2013 May; 123(5):353-7. PubMed ID: 23252596
[TBL] [Abstract][Full Text] [Related]
27. [Progressive multifocal leukoencephalopathy in a patient with multiple myeloma].
Willert CB; Engsig FN; Eskildsen HW; Andersen AB
Ugeskr Laeger; 2014 Dec; 176(49):. PubMed ID: 25497861
[TBL] [Abstract][Full Text] [Related]
28. The link between VLA-4 and JC virus reactivation.
Monaco MC; Major EO
Expert Rev Clin Immunol; 2012 Jan; 8(1):63-72. PubMed ID: 22149341
[TBL] [Abstract][Full Text] [Related]
29. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
30. Progressive multifocal leukoencephalopathy: JC virus induced demyelination in the immune compromised host.
Hou J; Major EO
J Neurovirol; 2000 May; 6 Suppl 2():S98-S100. PubMed ID: 10871795
[TBL] [Abstract][Full Text] [Related]
31. [Progressive multifocal encephalopathy in a LED patient].
Tikkakoski T; Ingo S; Julin L; Kanckos S
Duodecim; 2015; 131(10):950-3. PubMed ID: 26237874
[TBL] [Abstract][Full Text] [Related]
32. Treatment options for AIDS patients with progressive multifocal leukoencephalopathy.
Hernández B; Dronda F; Moreno S
Expert Opin Pharmacother; 2009 Feb; 10(3):403-16. PubMed ID: 19191678
[TBL] [Abstract][Full Text] [Related]
33. Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.
Ansell SM
Lancet Haematol; 2019 Jan; 6(1):e2-e3. PubMed ID: 30612711
[No Abstract] [Full Text] [Related]
34. Progressive multifocal leukoencephalopathy: new concepts.
Lima MA
Arq Neuropsiquiatr; 2013 Sep; 71(9B):699-702. PubMed ID: 24141508
[TBL] [Abstract][Full Text] [Related]
35. Progressive Multifocal Leukoencephalopathy.
Grebenciucova E; Berger JR
Neurol Clin; 2018 Nov; 36(4):739-750. PubMed ID: 30366552
[TBL] [Abstract][Full Text] [Related]
36. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic Experience of Progressive Multifocal Leukoencephalopathy Development during Ofatumumab Therapy for Chronic Lymphocytic Leukemia.
Hashimoto Y; Tashiro T; Ogawa R; Nakamichi K; Saijo M; Tateishi T
Intern Med; 2021 Dec; 60(24):3991-3993. PubMed ID: 34176829
[TBL] [Abstract][Full Text] [Related]
38. Mefloquine in the treatment of progressive multifocal leukoencephalopathy.
Gofton TE; Al-Khotani A; O'Farrell B; Ang LC; McLachlan RS
J Neurol Neurosurg Psychiatry; 2011 Apr; 82(4):452-5. PubMed ID: 20562463
[TBL] [Abstract][Full Text] [Related]
39. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
Redelman-Sidi G; Michielin O; Cervera C; Ribi C; Aguado JM; Fernández-Ruiz M; Manuel O
Clin Microbiol Infect; 2018 Jun; 24 Suppl 2(Suppl 2):S95-S107. PubMed ID: 29427804
[TBL] [Abstract][Full Text] [Related]
40. Management of infections by the human polyomavirus JC: past, present and future.
Hou J; Major E
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):629-40. PubMed ID: 16107201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
